What is AXIM Biotechnologies Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. AXIM Biotechnologies's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.02.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, AXIM Biotechnologies couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.
The historical rank and industry rank for AXIM Biotechnologies's Cash-to-Debt or its related term are showing as below:
AXIM'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.1 Max: 0.91
Current: 0.02
During the past 13 years, AXIM Biotechnologies's highest Cash to Debt Ratio was 0.91. The lowest was 0.00. And the median was 0.10.
AXIM Biotechnologies Cash-to-Debt Historical Data
The historical data trend for AXIM Biotechnologies's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
AXIM Biotechnologies Cash-to-Debt Chart
|
AXIM Biotechnologies Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Cash-to-Debt |
|
Get a 7-Day Free Trial
|
|
|
0.14 |
0.07 |
0.07 |
0.01 |
0.03 |
|
AXIM Biotechnologies Quarterly Data
|
|
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.01 |
0.02 |
- |
0.03 |
0.02 |
Competitive Comparison of AXIM Biotechnologies's Cash-to-Debt
For the Biotechnology subindustry, AXIM Biotechnologies's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AXIM Biotechnologies's Cash-to-Debt Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AXIM Biotechnologies's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where AXIM Biotechnologies's Cash-to-Debt falls into.
AXIM Biotechnologies Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
AXIM Biotechnologies's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
AXIM Biotechnologies's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AXIM Biotechnologies (AXIM Biotechnologies) Business Description
Traded in Other Exchanges
N/A
Address
6191 Cornerstone Court, E, Suite 114, San Diego, CA, USA, 92121
Axim Biotechnologies Inc is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, it owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells, as well as for oncological indications.
Executives
| Kurt Phinney |
officer: Chief Operating Officer |
6914 MAGELLAN WAY, SARASOTA FL 34243 |
| Peter O'rourke |
director |
C/O NORTHVIEW ACQUISITION CORP., 207 WEST 25TH STREET, 9TH FLOOR, NEW YORK NY 10001 |
| Catalina Valencia |
10 percent owner |
6191 CORNERSTONE COURT, E, SUITE 114, SAN DIEGO CA 92121 |
| Glycodots, Llc |
10 percent owner |
6191 CORNERSTONE COURT, E, SUITE 114, SAN DIEGO CA 92121 |
| Juniper & Ivy Corp |
10 percent owner |
5201 MEMORIAL DRIVE, SUITE 616, HOUSTON TX 77007 |
| Huemoeller John Walter Ii |
director |
305 SAN ANSELMO AVENUE, SUITE 300, SAN ANSELMO CA 94960 |
| Blake Schroeder |
director |
5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111 |
| Robert L Cunningham |
director |
5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111 |
| Timothy Richard Scott |
director |
5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111 |
| Robert Malasek |
officer: CFO |
PO BOX 235472, ENCINITAS CA 92023 |
| Lekhram Changoer |
10 percent owner |
18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022 |
| Medical Marijuana, Inc. |
10 percent owner |
12255 CROSTHWAITE CIRCLE, POWAY CA 92064 |
| Van Damme Philip A |
10 percent owner |
18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022 |
| Foundation Sanammad |
10 percent owner |
18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022 |
| George Anastassov |
10 percent owner |
18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022 |
AXIM Biotechnologies (AXIM Biotechnologies) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AXIM has been successfully added to your